Gemfibrozil(jem fi’ broe zil)
Apo-Gemfibrozil (CAN), Gen-Gemfibrozil (CAN), Lopid, PMS-Gemfibrozil (CAN)
PREGNANCY CATEGORY C
Drug class
Antihyperlipidemic
Therapeutic Actions
Inhibits peripheral lipolysis and decreases the hepatic excretion of free fatty acids; this reduces hepatic triglyceride production; inhibits synthesis of VLDL carrier apolipoprotein; decreases VLDL production; increases HDL concentration.
Indications
As adjunct to diet and exercise for hypertriglyceridemia in adult patients with very high elevations of triglyceride levels (types IV and V hyperlipidemia) at risk of pancreatitis unresponsive to diet therapy
As adjunct to diet and exercise in reduction of coronary heart disease risk in patients who have not responded to diet, exercise, and other drugs and have low HDL levels in addition to high LDL and triglyceride levels
Contraindications and Cautions
Contraindicated with allergy to gemfibrozil, hepatic or renal impairment, primary biliary cirrhosis, gallbladder disease.
Use cautiously with pregnancy, lactation, cholelithiasis, and renal impairment.
Available Forms
Tablets—600 mg
Dosages
Adults
Warning 1,200 mg/day PO in two divided doses, 30 min before morning and evening meals. Caution: Use only if strongly indicated and lipid studies show a definite response; hepatic tumorigenicity occurs in laboratory animals.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
